{
  "abstract": "Aim: Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.\n\nMethods: The adolescent PK study (NCT02512900), in adolescents aged 12–17 years with mild‐to‐moderate asthma, and TRAILHEAD (NCT04673630), in children aged 5–11 years with mild, moderate or severe asthma, were both open‐label, single‐dose, Phase 1 studies.\n\nResults: In the adolescent PK study, 21 adolescents (median age: 14 years) received a single 140‐mg subcutaneous tezepelumab dose. The mean maximum concentration (C max; 24.0 [SD: 6.6] μg/mL) was observed at a median time of 6 (range: 1–20) days postdose, with a mean terminal half‐life of 25.3 (SD: 4.7) days. The mean area under the concentration–time curve (AUC0–infinity) was 952 (SD: 289) μg*day/mL. In TRAILHEAD, 18 children (median age: 8 years) received a single 70‐mg subcutaneous tezepelumab dose. The C max (27.1 μg/mL [SD: 11.9]) was observed at a median time of 3.5 (range: 2–10) days postdose, with a mean terminal half‐life of 25.7 (SD: 5.9) days. The mean AUC0–infinity was 974 (SD: 320) μg*day/mL. Changes from baseline in blood eosinophil count, fractional exhaled nitric oxide and serum immunoglobulin E (IgE) reflected expected pharmacodynamic effects of tezepelumab. No new safety signals were identified.\n\nConclusions: These results were consistent with previous studies of tezepelumab in other groups, supporting development of tezepelumab for asthma in the paediatric population.",
  "abstract_shown": true,
  "affiliations": [
    "Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D AstraZeneca Gothenburg Sweden",
    "Centre for Genomics and Child Health, Blizard Institute Queen Mary University of London London UK",
    "Clinical Pharmacology, Modeling and Simulation Amgen Cambridge Massachusetts USA",
    "Department of Internal Medicine, Asthma and Allergy Medical University of Łódź Łódź Poland",
    "Biometrics, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Cambridge UK",
    "Biometrics, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Warsaw Poland",
    "Division of Paediatric Allergology University of Cape Town Cape Town South Africa",
    "Department of Paediatric Respiratory Medicine King's College Hospital London UK",
    "Faculty of Life Sciences and Medicine King's College London London UK",
    "School of Medicine, College of Medical, Veterinary & Life Sciences University of Glasgow Glasgow UK",
    "Department of Paediatric Respiratory Medicine Bristol Royal Hospital for Children Bristol UK",
    "Early Development Amgen Thousand Oaks California USA",
    "Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden",
    "Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Gaithersburg Maryland USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 15,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Anna Lundahl",
      "orcid": "0000-0003-0272-3192"
    },
    {
      "affs": [
        1
      ],
      "name": "Jonathan Grigg"
    },
    {
      "affs": [
        2
      ],
      "name": "Lubna Abuqayyas"
    },
    {
      "affs": [
        3
      ],
      "name": "Piotr Kuna"
    },
    {
      "affs": [
        4
      ],
      "name": "Gillian Hunter"
    },
    {
      "affs": [
        5
      ],
      "name": "Beata Pawlikowska"
    },
    {
      "affs": [
        0
      ],
      "name": "Jacob Leander",
      "orcid": "0000-0002-7411-2967"
    },
    {
      "affs": [
        6
      ],
      "name": "Michael Levin"
    },
    {
      "affs": [
        7,
        8
      ],
      "name": "Atul Gupta"
    },
    {
      "affs": [
        9
      ],
      "name": "James Paton"
    },
    {
      "affs": [
        10
      ],
      "name": "Katharine C. Pike"
    },
    {
      "affs": [
        11
      ],
      "name": "Jane R. Parnes"
    },
    {
      "affs": [
        12
      ],
      "name": "Gun Almqvist"
    },
    {
      "affs": [
        13
      ],
      "name": "Stephanie L. Roseti"
    },
    {
      "name": "the study investigators"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/b45ghnqtxg6me.bib",
  "cited_by": 1,
  "doi": "10.1002/bcp.70666",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13714621/",
  "id": "b45ghnqtxg6me",
  "issns": [
    "0306-5251",
    "1365-2125"
  ],
  "landing_url": "https://doi.org/10.1002/bcp.70666",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "2737|Asthma and respiratory diseases"
    ]
  ],
  "openalex": "W7167462608",
  "pdf_url": null,
  "pmcid": "PMC13714621",
  "pmid": "42409576",
  "published": "2026-07-06",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/b45ghnqtxg6me.ris",
  "sources": [
    {
      "first_seen": "2026-11-01T12:22:05Z",
      "native_id": "PMC13714621",
      "source": "pmc",
      "url": "https://doi.org/10.1002/bcp.70666"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2737|Asthma and respiratory diseases",
      "subfield": "physiology"
    }
  ],
  "title": "Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma",
  "title_text": "Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma",
  "type": "peer-reviewed",
  "updated_at": "2026-11-01T12:22:05Z",
  "url": "https://research.draconitic.com/paper/b45ghnqtxg6me",
  "venue": "British Journal of Clinical Pharmacology",
  "versions": []
}